Jonathan Tobin’s Post

💰BIO Roundup: Deal-Making Tips And Tricks • WHO SHOULD READ THIS? BD&L professionals in small companies looking for larger partners or investors. • WHAT IS IT? A round-up of insights gathered by Citeline News & Insights reporters from panel discussions and in exclusive interviews at the BIO International Conference on the subject of deal-making. • WHY IS IT IMPORTANT? Biotech companies are competing for the attention of potential partners to fund their R&D and help them achieve commercial success. This feature highlights key advice on decision-making, ranging from pipeline strategy to approaching international markets. Citeline Citeline Commercial #BIO2024

📣 Application call for our early-stage startups in drug development and delivery! 🗓️ Hand in your pitch deck until June 16, 2024 All details in the post below. #startups #entrepreneurship #lifesciences

At Clora, we’re dedicated to fostering innovation and collaboration within the biotech community. That’s why we’re thrilled to share highlights from the recent Bio-IT World Conference where our Founder & CEO, Rahul Chaturvedi moderated an insightful panel discussion on “Strategies for Biotech Success: Insights on Raising Capital from CEOs and VCs.” In an ever-evolving landscape, navigating capital acquisition is paramount for biotech companies. Rahul led the discussion, delving into recent shifts in funding trends, anticipating market expectations, and providing invaluable and actionable insights on selecting the right investors amidst competitive markets. Missed the discussion? Reach out / comment below ⬇ to learn more about how Clora is driving innovation and collaboration in the biotech landscape. 🌟 Many thanks to the amazing panelists - Kimberly Nearing from BVCF Management Ltd, Trevor Perry from Selas Ventures, Jami Rubin from Boundless Bio and ARCH Venture Partners, Chris Shibutani MD MBA from Goldman Sachs, and Scott Megaffin from Adiso Therapeutics. 🌟 #Biotech #BioITWorld #Clora #VC

Wow, October has gone by...really fast? In the hustle and bustle, I moderated a pair of panels for BioPharma Dive and PharmaVoice's The Next Frontier of the Life Sciences live event. We had plenty of intriguing commentary from experts Kevin Eisele, Dee Datta, Ph. D., Jordan Saxe ⛷️, Andrew Gengos and Edward M. Kaye, MD, which the wonderful Delilah Alvarado corralled into a story. Here are the takeaways about the emerging #biotechnology sector going into 2024: https://lnkd.in/grh2BZv7

How bad is this Biotech winter? I was advised to take a moderate view as it may not be as bad as it sounded initially. Yet I am seeing multiple Biotech companies and startups struggling. So how bad is this winter really? I spent the last couple of months talking to senior leaders who are active in the biotech scene regionally and globally. Below is what I concluded after consolidating their feedbacks: 1) While the public funds injected into the industry remains sturdy, but the amount of private funds diminished significantly resulted a much smaller collective pot. 2) There are more companies coming on to hunt for funds and for bigger funds as they need to cope with rising costs of development, operation, etc. that burn through their cash. Point 1 & 2 resulted in a situation where there simply isn’t enough funds to go around. This is not only true regionally but globally as well. 3) Investors are more cautious with their investment, opting for safer and more guaranteed returns as much as possible. Hence they are de-emphasizing on novelty but rather put money into those who have therapeutic development further down the development funnel. Hence those Biotechs that are more successful in fund raising are those having therapeutic development in later developmental stage. This is why Biotechs are consolidating efforts in this development race rather than diversifying to start new early stage projects. In conclusion, I think the question should not be asked how bad is this winter, but rather to understand how different this winter is. Let me know your comments and opinions. Thank you.

The past 3 years has been a roller coaster within the biotechnology industry following the "COVID-hype", the economic downturn, and with the "generalist" investors rapidly entering and more recently exiting the scene. The more specialized biotech VCs such as Sofinnova Partners and Medicxi are now once again leading the way when it comes to innovation in the industry! #biotechnology #investment #drugdevelopment

🔥🔥 The 2024 membership application for H7 Angel Club is officially open. Eligible investors can now access all membership benefits for free 👏 . H7 Angel Club, powered by H7 BioCapital, aims to provide a platform for angel investors, family funds and institutional investors to share resources and engage in professional investment discussions. We specialize in the field of life science/biotech and medtech, focusing on projects ranging from seed rounds to pre-IPO stages.  👉 Upon approval of membership application to H7 Angel Club, investors will enjoy the following benefits: - Invitations to regularly held deal sharing meetings - Access to high-quality projects in the field of life science/biotech and medtech - Networking opportunities with fellow investors and high-quality startups from the H7 network - Direct investment and follow-up investment opportunities 🎯 Apply for the investor membership: https://shorturl.at/losSW #angel #investmentopportunity #vc #healthcare #lifesciences #medtech #medicaldevices #biotech #biopharma #investors #familyoffice #syndicate

Interesting overview of JPM 2024 and the industry as a whole. https://lnkd.in/ghvYP7tS #pharmacompany #biotech #pharmajobs #biotechjobs #jpm2024

🔥 New Biotech Launch Alert! 🔥 A cutting-edge biotech company focused on inflammatory diseases has launched with an impressive $168M in funding! 🎉🧬 Leading this innovative venture is a former Kite leader, bringing a wealth of expertise and experience to the table. 🌟 Key investors in this venture include Atlas Venture, Omega Funds, and F-Prime Capital, whose support underscores the significant potential of this new company. 💡💰 With this substantial investment, the company is poised to develop groundbreaking treatments for inflammatory conditions, aiming to make a significant impact on patient care and outcomes. 🩺 #Biotech #InflammatoryDisease #HealthcareInnovation #FundingNews #BiotechLaunch #MedicalAdvancements #InnovationInHealthcare #ScientificResearch #Biopharma #NewBeginnings #AtlasVenture #OmegaFunds #FPrimeCapital

💸 Great news for the biotech startup ecosystem: Scion Life Sciences, a new biotech-focused VC, announced the close of its inaugural oversubscribed $310M fund... 👇 ❇️ Scion was founded by industry veterans Sam Hall, Aaron Kantoff, and Tadd Wessel. ❇️ Scion's strategy is to invest in promising biotech innovations, with potential investments ranging from a few thousand dollars in early stages to over $60 million across a company's life cycle. ❇️ The firm's investment approach is based on three pillars: mature therapeutic modalities, deep scientific understanding in specific areas, and solving clinical problems within the scope of independent biotech companies. ❇️ Scion is not just about creating exits but building sustainable biotech companies with the potential to reach valuations in the billions through the commercialization of transformative medicines. Original article: https://lnkd.in/g5PAZne8